Understand the source comparison
Tendon Repair Peptides 2026 Update: Research Compound Comparison
Before selecting a peptide for tendon repair research, compare mechanism, bioavailability, and practical administration requirements. The table below summarises the three primary peptides used in 2026 tendon research protocols. BPC-157 VEGF and FGF-2 upregulat
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide for tendon repair research, compare mechanism, bioavailability, and practical administration requirements. The table below summarises the three primary peptides used in 2026 tendon research protocols.
- BPC-157
- VEGF and FGF-2 upregulation; angiogenesis and collagen synthesis
- 12–18% systemic; 58–63% localized (scaffold delivery)
- Daily (systemic) or 2× weekly (localized)
- Phase IIb trial showed 47% increased Type I collagen with scaffold delivery
- Best for localized injury sites; systemic protocols now suboptimal
- TB-500
- Actin sequestration; fibroblast migration and MMP upregulation
- 65–72% subcutaneous
- Every 5 days (revised from 7–10 days)
- Half-life corrected from 10 days to 6.8 days in human plasma
- Reliable but requires more frequent dosing than older protocols suggested
- GHK-Cu
- TGF-beta modulation; collagen and decorin synthesis
- 8–12% standard; 38–42% liposomal
- Daily (liposomal)
- Liposomal encapsulation increased bioavailability 3–5×
- Only viable for tendon repair in liposomal form; non-liposomal versions ineffective